tci Medicare Compliance & Reimbursement - 2007 Issue 1
MEDICARE PART D: Democrats May Have The Wrong Idea About Negotiating Drug Prices, NCPA Claims
Subscribe or sign in to view the full article.
Article Overview
This article summarizes a policy-focused issue brief about Medicare Part D and government negotiation of prescription drug prices. It explains why the topic matters to Medicare policy, beneficiaries, insurers, and pharmaceutical manufacturers, and it reviews broad economic arguments and historical references used to assess whether negotiation authority would lead to lower costs.
Why This Topic Matters
It is relevant to readers tracking Medicare drug policy, federal pricing authority, and the broader debate over whether government negotiation can affect prescription drug spending.
What You Will Learn
- How the article frames the debate over Medicare Part D drug-price negotiation
- What broad economic and market-power arguments are discussed in relation to prescription drug pricing
- Why historical policy experience is referenced in the discussion of federal drug-pricing policy
- How the issue brief positions the potential impact of negotiation authority on Medicare and the private sector
Who Should Read This
- Medical coders and billing professionals monitoring Medicare policy changes
- Health policy analysts
- Payer and reimbursement professionals
- Pharmacy benefit and prescription drug stakeholders
- Healthcare administrators
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.


Quick, Current, Complete - www.findacode.com